About 5% of patients received appropriate discharges each year in this observational study.
The implantable cardioverter-defibrillator (ICD) is being used to reduce the risk for sudden death in many patients with hypertrophic cardiomyopathy (HCM). Whether these devices in fact are saving many lives is not known.
Investigators studied 506 unrelated patients with HCM identified on echocardiography who received an ICD at one of 42 centers in the U.S., Europe, and Australia. The average age of the patients was 42 years, and most received ICDs for primary prevention (n=383).
During a mean follow-up of 3.7 years, 20% of the patients had an appropriate device intervention, with the device terminating ventricular fibrillation or tachycardia and restoring sinus rhythm. Inappropriate shocks occurred in 27% of patients. The rate of appropriate…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association